The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion

Mitchell D Creinin, Eliane Shore, Shyamala Balasubramanian, Bryna Harwood

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Our objective was to evaluate relative differences in direct and total (direct and indirect) costs for medical abortion regimens using mifepristone and misoprostol or misoprostol alone. We created formulas to evaluate relative differences in costs in the United States, Chennai (Madras), India, and a hypothetical developing country based on published protocols and efficacy data. Follow-up visits and suction aspiration procedures in the United States were evaluated over a range of costs. American indirect costs were estimated using earning data. Indirect costs in India and the hypothetical developing country were based on mifepristone cost differences between the United States and India. Although mifepristone costs US$83.33 for every 200-mg tablet in the United States, the actual excess cost of using a mifepristone regimen, as compared with a misoprostol-alone regimen, is only US$22 to US$32. The actual cost of a mifepristone regimen is lower than that of a misoprostol-alone regimen in India. In a hypothetical developing country, a mifepristone regimen is likely to be less expensive than regimens using misoprostol alone. Because of the higher efficacy of medical abortion regimens using mifepristone and misoprostol and the need for fewer follow-up evaluations, such regimens are less expensive or only minimally more expensive than those using misoprostol alone.

Original languageEnglish (US)
Pages (from-to)26-30
Number of pages5
JournalContraception
Volume71
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Misoprostol
Mifepristone
Costs and Cost Analysis
India
Developing Countries
Suction
Tablets

Keywords

  • Cost
  • Medical abortion
  • Mifepristone
  • Misoprostol

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion. / Creinin, Mitchell D; Shore, Eliane; Balasubramanian, Shyamala; Harwood, Bryna.

In: Contraception, Vol. 71, No. 1, 01.2005, p. 26-30.

Research output: Contribution to journalArticle

Creinin, Mitchell D ; Shore, Eliane ; Balasubramanian, Shyamala ; Harwood, Bryna. / The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion. In: Contraception. 2005 ; Vol. 71, No. 1. pp. 26-30.
@article{c97ea634cb1e4222805f86510f04acf9,
title = "The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion",
abstract = "Our objective was to evaluate relative differences in direct and total (direct and indirect) costs for medical abortion regimens using mifepristone and misoprostol or misoprostol alone. We created formulas to evaluate relative differences in costs in the United States, Chennai (Madras), India, and a hypothetical developing country based on published protocols and efficacy data. Follow-up visits and suction aspiration procedures in the United States were evaluated over a range of costs. American indirect costs were estimated using earning data. Indirect costs in India and the hypothetical developing country were based on mifepristone cost differences between the United States and India. Although mifepristone costs US$83.33 for every 200-mg tablet in the United States, the actual excess cost of using a mifepristone regimen, as compared with a misoprostol-alone regimen, is only US$22 to US$32. The actual cost of a mifepristone regimen is lower than that of a misoprostol-alone regimen in India. In a hypothetical developing country, a mifepristone regimen is likely to be less expensive than regimens using misoprostol alone. Because of the higher efficacy of medical abortion regimens using mifepristone and misoprostol and the need for fewer follow-up evaluations, such regimens are less expensive or only minimally more expensive than those using misoprostol alone.",
keywords = "Cost, Medical abortion, Mifepristone, Misoprostol",
author = "Creinin, {Mitchell D} and Eliane Shore and Shyamala Balasubramanian and Bryna Harwood",
year = "2005",
month = "1",
doi = "10.1016/j.contraception.2004.07.011",
language = "English (US)",
volume = "71",
pages = "26--30",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion

AU - Creinin, Mitchell D

AU - Shore, Eliane

AU - Balasubramanian, Shyamala

AU - Harwood, Bryna

PY - 2005/1

Y1 - 2005/1

N2 - Our objective was to evaluate relative differences in direct and total (direct and indirect) costs for medical abortion regimens using mifepristone and misoprostol or misoprostol alone. We created formulas to evaluate relative differences in costs in the United States, Chennai (Madras), India, and a hypothetical developing country based on published protocols and efficacy data. Follow-up visits and suction aspiration procedures in the United States were evaluated over a range of costs. American indirect costs were estimated using earning data. Indirect costs in India and the hypothetical developing country were based on mifepristone cost differences between the United States and India. Although mifepristone costs US$83.33 for every 200-mg tablet in the United States, the actual excess cost of using a mifepristone regimen, as compared with a misoprostol-alone regimen, is only US$22 to US$32. The actual cost of a mifepristone regimen is lower than that of a misoprostol-alone regimen in India. In a hypothetical developing country, a mifepristone regimen is likely to be less expensive than regimens using misoprostol alone. Because of the higher efficacy of medical abortion regimens using mifepristone and misoprostol and the need for fewer follow-up evaluations, such regimens are less expensive or only minimally more expensive than those using misoprostol alone.

AB - Our objective was to evaluate relative differences in direct and total (direct and indirect) costs for medical abortion regimens using mifepristone and misoprostol or misoprostol alone. We created formulas to evaluate relative differences in costs in the United States, Chennai (Madras), India, and a hypothetical developing country based on published protocols and efficacy data. Follow-up visits and suction aspiration procedures in the United States were evaluated over a range of costs. American indirect costs were estimated using earning data. Indirect costs in India and the hypothetical developing country were based on mifepristone cost differences between the United States and India. Although mifepristone costs US$83.33 for every 200-mg tablet in the United States, the actual excess cost of using a mifepristone regimen, as compared with a misoprostol-alone regimen, is only US$22 to US$32. The actual cost of a mifepristone regimen is lower than that of a misoprostol-alone regimen in India. In a hypothetical developing country, a mifepristone regimen is likely to be less expensive than regimens using misoprostol alone. Because of the higher efficacy of medical abortion regimens using mifepristone and misoprostol and the need for fewer follow-up evaluations, such regimens are less expensive or only minimally more expensive than those using misoprostol alone.

KW - Cost

KW - Medical abortion

KW - Mifepristone

KW - Misoprostol

UR - http://www.scopus.com/inward/record.url?scp=27744572650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744572650&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2004.07.011

DO - 10.1016/j.contraception.2004.07.011

M3 - Article

C2 - 15639068

AN - SCOPUS:27744572650

VL - 71

SP - 26

EP - 30

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -